CN1616091A - Compound protease medicine for treating prostate proliferation and its preparing method - Google Patents
Compound protease medicine for treating prostate proliferation and its preparing method Download PDFInfo
- Publication number
- CN1616091A CN1616091A CN 200410060863 CN200410060863A CN1616091A CN 1616091 A CN1616091 A CN 1616091A CN 200410060863 CN200410060863 CN 200410060863 CN 200410060863 A CN200410060863 A CN 200410060863A CN 1616091 A CN1616091 A CN 1616091A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- hyperplasia
- medicine
- collagenase
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
The compound protease medicine for treating prostate proliferation consists of hyaluronidase, collagenase, desoxyribonuclease and other protease as well as antibiotic, chitosan and other supplementary material. The preparation process includes weighing material in certain proportion; dissolving agarose in solvent and disinfection; preparing chitosan gel and mixing with medicine; adding material into the buffering liquid with calcium and zinc ions, dissolving and mixing; disinfection, detecting endotoxin content, freeze drying into powder in bacteria-free condition and packing. The present invention has high curative effect, low cost, high stability of product and other advantages.
Description
Technical field
The invention belongs to the biological medicine technology field, more specifically relate to a kind of compound recipe protease medicine that is used for the treatment of hyperplasia of prostate, also relate to the preparation method of this medicine simultaneously.
Background technology
Hyperplasia of prostate is to follow male's aging and a kind of commonly encountered diseases of occurring.Along with the progress and the growth in the living standard of medical skill, the life-span of China's population obviously prolongs.The sickness rate of hyperplasia of prostate also rises year by year.According to statistics, China has the hyperplasia of prostate needs of patients treatment more than 8,000 ten thousand at present at least.Because the deficiency (equipment, technology) of health resources and effective treatment means are few, and expensive medical expense, cause most patients disease torment at one's discretion, be in the not condition of system's regular treatment, quality of life causes anxiety.
The method of treatment prostatic hyperplasia is divided into Drug therapy, physical therapy and operative treatment substantially.The dysuria that hyperplasia of prostate causes mainly is divided into two kinds of mechanicalness factor and dynamic property factors.Medicine is divided into two classes: a class is the 5 inhibitor, as proscar, epristeride etc.Another kind of is the α receptor blocking agent.As breathe out happy, China etc. how.With proscar (development of U.S. MSD Corp.) is example, and about 25-40% patient's prostate volume just begins to have to dwindle after the half a year of need taking medicine, but still need take medicine all the life subsequently.Otherwise, drug withdrawal midway, body of gland can be grown up again.Take for a long time, expense is high.So can adhere to that the patient who treats is few.Physical therapy (microwave, radio frequency etc.) effect is of short duration and not obvious, has been superseded gesture.Based on transurethral resection of prostate, curative effect is better at present for operative treatment, but needs anesthesia and have operation risk, and complication also happens occasionally.It is 0.2% that the intraoperative death rate of report resection of prostate is arranged, and the postoperative complication incidence rate is 18% (Mebust WK, et al.J Urol1989; 141:243-247).Account for absolute majority with gerontal patient more than 60 years old among the hyperplasia of prostate patient, the patient is because of the heart, brain, lung, liver, kidney, diabetes etc. can not tolerate anesthesia and operator not within minority.Patient advanced age, suffer from multiple disease again simultaneously, the psychology of fearing operation is very strong, so pump up a kind of safe, effective, misery is little, expense is few Therapeutic Method can be arranged.
Longo in 1972 etc. are first with the supplementary means of collagenase as the prostate cold therapy, and Gocken in 1992 etc. have carried out the zoopery of ablation of prostate.Mix with collagenase with the dog prostata tissue that exsomatizes, prostata tissue dissolves gradually as a result.Barrett in 1996 etc. are expelled to the enzyme of combination in the prostate body of gland of old dog, the local gland tissue that found that drug injection site is spongiform change, but the effect of dwindling prostate volume is also not obvious, and its histolytic effectiveness is obviously poor than experiment in vitro.And the animal serum enzymatic activity of being tried raises more than 10 times, shows that injectable drug has whole body to absorb and the liver function of animal is had negative effect.Because the numerous problem of effect finite sum of experiment fails to illustrate in the body, do not see the report of clinical practice so far both at home and abroad yet.
Summary of the invention
The object of the present invention is to provide a kind of compound recipe protease medicine for the treatment of hyperplasia of prostate.This prescription rationally, and is easy to use, safe and effective, with low cost.Through zoopery and clinical observation: this medicine can make the rapid deactivation of organizing of injection zone, protein coagulation, degeneration, sealing regional flow, the side effect of having avoided whole body to absorb.Under the combined effect of functional enzyme, the gland tissue of degeneration is dissolved, variation such as Proteolytic enzyme, tissue liquefaction.It can not only make the change on the gland tissue genetic morphology of injection zone, and atrophy finally appears in body of gland, and volume-diminished is so can effectively remove the symptom of urinating and blocking.
Another object of the present invention has been to provide a kind of method for preparing compound recipe protease medicine, and technology is simple, stable performance, and it is convenient to store, and is suitable for mass production.
For many years, owing to be subjected to the inspiration of tissue culture and cell culture, begun the experimental exploring of enzyme process dissolving prostata tissue.Prostata tissue is rich in collagen and proteoglycan.Form multiple spherical shape tuberosity during prostatic hyperplasia in the body of gland, contain a large amount of collagen fiber in the tuberosity.Hydroxyproline content increases in the body of gland, makes fibrous tissue stiff, tetanic, collagen forfeiture elasticity, and then cause that mechanical urinating be obstructed.Contain a large amount of α receptors in prostata tissue and the neck of bladder sphincter, it is controlling the contraction of smooth muscle, and influence is urinated.Prostatic hyperplasia mainly is based on interstitial proliferation.Between can rise to hypertrophy by just often 2: 1 time 5: 1 of the ratio of matter and epithelium.According to these characteristics of prostatic hyperplasia, it makes (consumption is a weight portion) by following raw materials according compound recipe protease medicine:
Hyaluronidase 0.3-1.5 bromelain 0.2-1.0 trypsin 0.2-2.5
Bacillus polymyxa Neutral proteinase 0.1-0.8 collagenase 0.2-1.5 gentamycin 0.02-0.1
Dexamethasone 0.02-0.1 deoxyribonuclease 0.1-0.5 chitosan 0.00-0.1
Terazosin 0.0-1.5 mannitol 0.0-2.0 agarose 0.2-1.2
TritonX 0.2-1.5
A kind of preparation process of compound recipe protease medicine for the treatment of hyperplasia of prostate is as follows:
1. take by weighing above-mentioned each raw material in proportion.
2. mannitol (only using agarose among the embodiment 3) and agarose are dissolved in respectively in the solvent, it is standby to sterilize.
3. prepare chitosan gel rubber slow releasing agent (embodiment 3 and 6 can save this step).
● the spirit of vinegar of preparation 0.1mol/L.
● add 2% chitosan, stirring is dissolved it fully.
● regulate between the pH to 5.5-6.0 with the 1mol/L sodium hydroxide, be the spirit of vinegar chitosan solution.
● the spirit of vinegar chitosan solution is added in the terazosin, fully stirring and dissolving.
4. in the buffer that contains calcium, zinc ion, add chitosan gel rubber slow releasing agent and hyaluronidase, bromelain, trypsin, Bacillus polymyxa Neutral proteinase, collagenase, gentamycin, dexamethasone, deoxyribonuclease, TritonX, dissolving and mixing respectively.If preparation is improper, can cause the solution muddiness.
5. after degerming, detect the endotoxin content of preparation.Freeze dried powder is made in qualified back under aseptic condition, packing is stand-by.
The present invention has finished experiment in vitro and the human clinical observes.When testing with the prostata tissue that exsomatizes, this medicine is lytic gland soma rapidly; A certain amount of enzymatic solution of injection in the prostate body of gland that exsomatizes, injection zone caves in, is cellular change in 24 hours, and peripheral body of gland subsides, tissue liquefaction as gelatin; And the body of gland of injection solution no change still not.After having injected this preparation in the prostate body of gland of 12 old dogs, the observation that lasts 4 months, animal all survives.Prostate size before and after the medicine injection is seen Fig. 1, Fig. 2.B ultrasonic and measured result show: the prostate body of gland has dwindled 42-70% before the injection, sees Table 2; Tangible cavity be can see in the body of gland, Fig. 3, Fig. 4, Fig. 5 seen.Inject and be also shown in liquefaction tissue residual in the cavity after 4 months in the body of gland.Confirm after deliberation: along with the prolongation of time, the body of gland internal cavity is with closure, and the body of gland volume also can further dwindle, and sees Fig. 6.Simultaneously, whole body of gland is the change of sponge sample, body of gland capsuleization.Histological observation is found: the glandular tube chamber dwindles obviously, karyopyknosis, smooth muscle fiber fracture.All sign explanations: the gland tissue of medicine injection is inactivation, tissue liquefaction.Research worker has also been observed the toxicity of said preparation.Carried out the serum enzyme labeled compound assay before injecting the back the 2nd day, 30 days and putting to death, the result is relatively preceding with injection, difference that there are no significant.After showing the interior injection of this preparation body of gland, no whole body absorbs, and can not bring liver injury.Over one year, under numerous volunteers' an urgent demand,, select advanced age or patient that can not tolerate surgery to carry out clinical experiment through strict organization procedure.Before the applying date, 22 routine patients have been treated.By follow-up observation more than a year, behind the patient infusion in January symptom just have clear improvement, the night urination number of times reduces (patient by being reduced to 0-2 time/night at original 6-10 time/night), the urine flow rate is multiplied, and urinates line and increases slightly, urinates effectively.B ultrasonic is measured prostate volume and is dwindled about 50%, sees Table 1.Last observation more than a year, the patient feels quite pleased therapeutic effect, inject said preparation certainly after, took the medicine of any treatment prostatic hyperplasia never again.Because in vivo test is to carry out, marked difference is arranged when its situation and stripped (under tissue devitalization's condition) in the organism of living.Vasoganglion is very abundant in the prostate body of gland, and as blocking blood flow not, the enzymatic solution of injection can reduce the drug level of local organization rapidly to the whole body diffusion; The mortifier that also has plurality of enzymes in addition in the body.As not eliminating these influence factors, the effect of enzyme will be had a greatly reduced quality; As absorb excessively, and also can increase the burden of liver, cause that liver function one crosses sexual abnormality.Confirm through zoopery and clinical practice: this formula combination can be brought into play the synergism of various compositions better.The activity of demolition purpose tissue and original structure targetedly under the combined effect of plurality of enzymes.Treated agarose can effectively destroy the intravital mortifier of gland, make the injection zone tissue that albuminous degeneration take place, solidify, cause tissue devitalization's (similar isolated condition), thereafter the compound recipe enzymatic solution that reinjects just can reach and dissolve body of gland, liquefaction, softening tissue, dwindles the effect of body of gland volume.The compound recipe protease preparation possesses following several effect at least.
1. make injection zone tissue devitalization, albuminous degeneration, coagulation necrosis, minimizing and occluding vascular, blocking blood flow.
2. by the Digestion of enzyme, tissue is dissociated into cell mass or individual cells.Under the effect of functional enzyme, make exfoliative cyte further lose adhesive ability and multiplication capacity again.In other words, through after a series of variations, local organization has lost regenerated primary condition.So think: the effectiveness of this technology is trustworthy.
3. the gland tissue of degeneration dissolves, liquefies, and scope progressively spreads to periphery.Injection zone visible " opaque dark area of fluid " under the B ultrasonic.
4. liquefaction is organized in the unified regulation and control of body down, and a part is handled by the intravital macrophage phagocytic of gland, and another part flows into urethra through glandular tube, excretes.Body of gland is softening, volume-diminished.
5. histological examination is shown: the atrophy of injection zone glandular tube, and the glandular epithelium karyopycnosis, the muscle fiber fracture, it is loose netted that a matter is.Above-mentioned variation prompting: the tissue after the enzyme dissolving gangrenosum acne occurs and changes, and the character of its variation should be irreversible.Inference thus: the effect of this treatment should be secular.
6. after the clinical practice, patient's non-evident effect.Do not see heating, allergy, liver, renal function injury show after enzymatic solution is injected only to be defined in around the injection zone that to the organ beyond the body of gland and harmless, no whole body absorbs.
7. agarose has dual function.Solidified structure, sealing blood vessels destroys the α receptor; Under the bio-electric field effect, help the diffusion of enzyme, enlarge the scope of dissolving tissue and strengthen liquefaction.
The present invention compared with prior art has the following advantages and characteristics.
One. determined curative effect.Effective percentage reaches (the experiment initial stage is because of lacking experience, so influenced therapeutic effect) more than 90%, along with empirical accumulation, believes that curative effect also can improve, and this result is higher than present medication effect far away.
Two. indication is wide, and is safe.Various high risk patients, the equal injectable of patient that the heart, brain, pulmonary function difference can not tolerate surgery.
Three. method is easy.General patient only need inject once and can take effect, and after this withdraws the medicine of all treatment prostatic hyperplasia.
Four. this law is delivered to medicine in the prostate by injecting pathway.Dwindling prostate volume is liquefied by body of gland and realizes.Its maximum characteristics are that wound is little, have kept the integrity of prostatic urethra, do not damage urethra; And existing " electrotomy " the excision prostata tissue of performing a surgical operation in the urethra, so be conspicuous to the damage of urethra.Patient's post-operative recovery is slow.
Five. medical expense is low, reduces more than 60% than expenses of surgical treatment.
Six. the no whole body of injection absorbs in the body of gland, can not cause harmful effect to the patient.The present invention is applicable to hyperplasia of prostate, chronic prostatitis (married, do not educate person).The inventive method safety, no pain, good effect, expense are few in a word, and rehabilitation is fast.For inoperable patient, provide a kind of ideal method undoubtedly.The said preparation raw material sources are wide, and properties of product are stable, are suitable for large-scale production, the market prospect optimism, and social benefit and economic benefit are huge.
Description of drawings
Fig. 1: prostate size before the old dog medicine injection.(5.8 about footpath) * 5.0 (footpath up and down) * 4.0 (anteroposterior diameter)=116cm
3, disappearence of central groove.
Fig. 2: medicine is injected back 114 days prostate sizes, injects front volume and dwindles 61.2%.(4.9 about footpath) * 3.75 (footpath up and down) * 2.45 (anteroposterior diameter)=45cm
3, Rolandic fissure reappears.
Fig. 3: medicine is injected back 7 days B ultrasonic and is shown the drug effect zone, and boundary is fully aware of
Fig. 4: medicine is injected back 14 days B ultrasonic and is shown that the left side body of gland has a cavity, 1.6cm * 1.4cm
Fig. 5: medicine is injected back 28 days B ultrasonic and is shown that the right side body of gland has a cavity, 1.4cm * 1.2cm
Fig. 6: medicine is injected the longitudinal section of back 114 days prostate bodies of gland, a cavity is respectively arranged still for closed in the body of gland of the left and right sides, coincide with the B ultrasonic finding
The specific embodiment
Embodiment 1:
A kind of compound recipe protease medicine for the treatment of hyperplasia of prostate, it makes (consumption is a weight portion) by following raw materials:
Hyaluronidase 1.5 bromelain 0.2 trypsin 0.5
Bacillus polymyxa Neutral proteinase 0.1 collagenase 0.2 gentamycin 0.02
Dexamethasone 0.1 deoxyribonuclease 0.1 chitosan 0.03
Terazosin 0.2 mannitol 0.5 agarose 0.4
TritonX 0.2
Its preparation process is as follows:
1. take by weighing above-mentioned each raw material in proportion.
2. mannitol and agarose are dissolved in respectively in the specified solvent, it is standby to sterilize.
3. prepare the chitosan gel rubber slow releasing agent
● the spirit of vinegar of preparation 0.1mol/L.
● add 2% chitosan, stirring is dissolved it fully.
● regulate between the pH to 5.5--6.0 with the 1mol/L sodium hydroxide, be the spirit of vinegar chitosan solution.
● the spirit of vinegar chitosan solution is added in the terazosin, fully stirring and dissolving.
4. in the buffer that contains calcium, zinc ion, add hyaluronidase, bromelain, trypsin, Bacillus polymyxa Neutral proteinase, collagenase, gentamycin, dexamethasone, deoxyribonuclease, TritonX respectively and add each component, dissolving and mixing.
5. after the sterilization degerming, detect the endotoxin content of preparation.Freeze dried powder is made in qualified back under aseptic condition, packing is stand-by.
Embodiment 2:
A kind of compound recipe protease medicine for the treatment of hyperplasia of prostate, it makes (consumption is a weight portion) by following raw materials:
Hyaluronidase 0.5 bromelain 1.0 trypsin 1.5
Bacillus polymyxa Neutral proteinase 0.8 collagenase 0.5 gentamycin 0.02
Dexamethasone 0.02 deoxyribonuclease 0.5 chitosan 0.04
Terazosin 0.5 mannitol 1.8 agaroses 0.3
TritonX 0.2
Preparation process is identical with embodiment 1.
Embodiment 3:
A kind of compound recipe protease medicine for the treatment of hyperplasia of prostate, it makes (consumption is a weight portion) by following raw materials:
Hyaluronidase 0.3 bromelain 0.3 trypsin 1.5
Bacillus polymyxa Neutral proteinase 0.5 collagenase 1.5 gentamycins 0.02
Dexamethasone 0.04 deoxyribonuclease 0.2 TritonX 0.5
Agarose 1.0
Preparation process is identical with embodiment 1.
Embodiment 4:
A kind of compound recipe protease medicine for the treatment of hyperplasia of prostate, it makes (consumption is a weight portion) by following raw materials:
Hyaluronidase 1.5 bromelain 0.5 trypsin 0.2
Bacillus polymyxa Neutral proteinase 0.5 collagenase 0.5 gentamycin 0.02
Dexamethasone 0.05 deoxyribonuclease 0.4 chitosan 0.03
Terazosin 1.0 mannitol 1.8 agaroses 0.2
TritonX 0.5
Preparation process is identical with embodiment 1
Embodiment 5:
A kind of compound recipe protease medicine for the treatment of hyperplasia of prostate, it makes (consumption is a weight portion) by following raw materials:
Hyaluronidase 0.5 bromelain 0.8 trypsin 0.75
Bacillus polymyxa Neutral proteinase 0.5 collagenase 0.5 gentamycin 0.1
Dexamethasone 0.05 deoxyribonuclease 0.1 chitosan 0.08
Terazosin 1.5 mannitol 0.5 agarose 1.2
TritonX 0.5
Preparation process is identical with embodiment 1
Embodiment 6:
A kind of compound recipe protease medicine for the treatment of hyperplasia of prostate, it makes (consumption is a weight portion) by following raw materials:
Hyaluronidase 1.0 bromelain 0.6 trypsin 2.5
Bacillus polymyxa Neutral proteinase 0.5 collagenase 1.0 gentamycins 0.02
Dexamethasone 0.05 deoxyribonuclease 0.2 mannitol 1.6
Agarose 0.5 TritonX 1.0
Preparation process is identical with embodiment 1
Embodiment 7:
A kind of compound recipe protease medicine for the treatment of hyperplasia of prostate, it makes (consumption is a weight portion) by following raw materials:
Hyaluronidase 1.2 bromelain 0.6 trypsin 0.75
Bacillus polymyxa Neutral proteinase 0.25 collagenase 1.5 gentamycins 0.05
Dexamethasone 0.05 deoxyribonuclease 0.5 chitosan 0.10
Terazosin 0.5 mannitol 1.0 agaroses 0.25
TritonX 1.5
Preparation process is identical with embodiment 1
Embodiment 8:
A kind of compound recipe protease medicine for the treatment of hyperplasia of prostate, it makes (consumption is a weight portion) by following raw materials:
Hyaluronidase 1.0 bromelain 1.0 trypsin 2.5
Bacillus polymyxa Neutral proteinase 0.5 collagenase 1.0 gentamycins 0.02
Dexamethasone 0.1 deoxyribonuclease 0.2 chitosan 0.06
Terazosin 0.5 mannitol 1.6 agaroses 0.5
TritonX 1.0
Preparation process is identical with embodiment 1
After finishing formula development, zoopery and clinical experiment have been carried out.
Got stripped prostata tissue and medicament mixed incubation 2 hours, the most of dissolving of gland tissue, the solution muddiness is observed the histiocyte that as seen comes off in a large number; A certain amount of enzymatic solution of injection in the prostate body of gland that exsomatizes, is cellular change at injection zone depression in 24 hours, and peripheral body of gland subsides, tissue liquefaction as gelatin, and the body of gland of injection solution no change still not.After having injected this preparation in the prostate body of gland of 12 old dogs, the observation that lasts 4 months, animal survives well.B ultrasonic and measured result show: the prostate body of gland has dwindled 42-70% before the injection; The medicine injection was also shown in tangible cavity in the body of gland after 4 months.The residual tissue that liquefaction is arranged in the cavity.Confirm after deliberation: along with the prolongation of time, the body of gland internal cavity is with closure, and the body of gland volume also can further dwindle.Simultaneously, whole body of gland is the change of sponge sample, body of gland capsuleization.Histological observation is found: the glandular tube chamber dwindles obviously, karyopyknosis, smooth muscle fiber fracture.All sign explanations: the gland tissue inactivation of medicine injection, tissue liquefaction.Be to observe side effects of pharmaceutical drugs, extract injection back the 2nd day, 30 days and put to death before animal serum, measured the variation of sero-enzyme, before result and the injection relatively, the index of the various reaction hearts, liver, renal function there are no significant difference.After showing the interior injection of this preparation body of gland, no whole body absorbs.Show the safe of medicine.Through after the adequate preparation, through strict organization procedure, People's Hospital, Hubei Province selected advanced age or patient that can not tolerate surgery to carry out clinical experiment under numerous volunteers' an urgent demand in 2003.Before the applying date, 22 routine patients have been treated.By follow-up observation more than a year, behind the patient infusion in January symptom just have clear improvement, along with the prolongation of time, doing well,improving is more and more obvious.The night urination number of times reduces, and by being reduced to 0-2 time/night, the urine flow rate is multiplied at original 6-10 time/night, and the urine line increases slightly, and it is strong to urinate.B ultrasonic is measured prostate volume and is dwindled about 50%.Confirm through zoopery and clinical practice: this combination can be brought into play the synergism of various compositions better.The activity of demolition purpose tissue and original structure targetedly under the combined effect of plurality of enzymes.Treated agarose can effectively destroy the intravital mortifier of gland, make the injection zone tissue that albuminous degeneration take place, solidify, cause tissue devitalization's (similar isolated condition), the compound recipe enzymatic solution that reinjects just can reach and dissolve body of gland, liquefaction, softening tissue, dwindles the effect of body of gland volume.
Table 1: situation variation more than 3 months behind the prostatic hyperplasia patient treatment
Patient treatment time symptom B ultrasonic measurement prostate volume volume contracts and treats the back situation
(cubic centimetre) little %
After treating before the treatment
Liu * *, on July 31st, 2003 dysuria 4 years 7-8 time/72.56 36.71 50% unobstructed micturitions, evening
74 years old nocturia are urinated not to the utmost and are seen in the thin body of gland of line and do not get up in the night to urinate on 5, suffer from
Individual size not person is satisfied
Deng cavity
Yu * *, year 5-6 145.15 83.50 42.4% unobstructed micturitions surplus on August 22nd, 2003 dysuria 10, urine
Thin unable the flow rate of 74 years old times/nocturia line increases by one
Disconnected urinating doubly
Lee * *, JIUYUE in 2003 dysuria on the 11st 175.5 80.06 54.4% was treated back January in nearly 20 years gradually
Increase the weight of 5-6 time/night in 58 years old and once obeyed the guarantor so far, withdraw institute
Pleasure is controlled, breathed out to row, Phenoxybenzamine does not have medicine, urinates
Imitate the obvious hypertrophy of two lateral lobes, in unobstructed
Pallette goes into bladder and sees a large amount of cells
Girder
Liu * *, on October 1st, 2003, dysuria 11 years was pulled out the fistulation pipe because of urine pool 196.37 98.3 50%,
Stayed capable bladder stoma 7-8 in July lobus lateralis dexter to see voluntary micturition in 78 years old, row
Inferior/the spherical 1.0 * 1.6cm of increase of prostate at night urinates unimpeded
Middle period, obvious hypertrophy had serious dark space
Emphysema
Yellow * *, 3 years urine of December in 2003 dysuria on the 3rd waits for that 90 52.4 42.2% urine lines increase slightly disease
But the urine line carefully had urine retention to put shape disappearance in the pipe body of gland in 68 years old
The history informal dress is breathed out pleasure, proscar, is seen
Phenoxybenzamine unsatisfactory curative effect 5-6 1.6 * 1.7 skies
Inferior/night the chamber
The week * *, after waiting for for 83.5 51.3 40% January, pulls out in 10 years urine of dysuria on February 12nd, 2004
It is unobstructed that 83 years old urine lines carefully have urine retention to put bank of tubes urine, urinary catheter, and it is smooth to urinate
That 14 days informal dresses are breathed out is happy, protect the row urinary catheter pulls out logically, and patient is satisfied
Control, the Phenoxybenzamine unsatisfactory curative effect
5-6 time/night
Wu * *, 8 years 4 101.52 50.2 50.6% symptoms of gradual dysuria on March 5th, 2004 disappear fully
65 years old times/once obeying multiple medicine night does not have unobstructed micturition, removes, and patient is very
Imitating has 5 years urinary catheters of high coronary disease medical history to pull out satisfaction
Can not perform the operation
Du * *, on March 9th, 2004, gradual dysuria was 1 year, and 64.3 38.5 40% symptoms disappear fully
75 years old 7-8 time every night, the urine line is thin, and unobstructed micturition removes, and patient very
High coronary disease medical history 3 years are arranged, dissatisfied
Can operation
Grandson * *, on April 28th, 2004, dysuria was 7 years, and the urine line is thin, and 63.7 35 45.1% symptoms disappear fully
Had in 55 years old to be interrupted and urinate, the 5-6 unobstructed micturition removes every night, and patient very
Inferior, the operation of being unwilling, the satisfaction of taking medicine, every night 0
Invalid-1 time
Old * *, on June 9th, 2004 frequent urination at night, dysuria 10 58.6 32.2 45% symptoms disappear fully
69 years old surplus year, 4-5 time every night, big unobstructed micturition removed, and patient very
Just freely satisfied, every night 0
-1 time, defecation
Unobstructed
Pan * *, on June 10th, 2004 frequent urination at night, dysuria 8 years, 54.5 31.2 42.8% symptoms obviously disappear
The urine line was thin in 73 years old, and the urethral catheterization history is arranged 3 times, and unobstructed micturition removes, and it is logical to urinate
It is invalid to obey multiple medicine, and serious smooth, patient very
Emphysema, 6-8 time every night, satisfied
Be unwilling to perform the operation
Lee * *, on June 10th, 2004, dysuria was 8 years, and the urine pool is arranged, and 120.7 64.5 46.6% urinary catheters are pulled out, row
Lasting urethral catheterization was 14 days in 77 years old, and serious lung unobstructed micturition urine is unobstructed, patient
Edema due to disorder of QI, 8-10 time every night, very satisfied
Can not perform the operation
Table 2: dog prostate volume, variable density before and after the enzymatic solution injection
Reduction volume in injection back accounts for body of gland weight body of gland density before the sequence number injection
Volume (cm
3) volume (cm
3/ ml) original volume (%) (g) (g/ml)
1 28.6 11.2/10.2 60.84 9.8 0.961
2 30.6 14.5/14.8 52.61 14.3 0.966
3 26.7 15.7/15.2 41.20 15.0 0.987
4 36.4 10.8/9.6 70.33 9.5 0.989
5 24.6 12.3/12.8 50.00 11.9 0.930
6 28.8 16.3/16.5 43.40 16.1 0.976
7 23.2 12.7/13.0 45.26 12.7 0.977
8 20.3 11.5/10.8 43.35 10.3 0.954
9 67.8 37.2/35.7 45.13 34.8 0.974
10 73.5 42.6/41.9 42.04 40.3 0.962
11 117.2 48.3/45.4 58.79 44.3 0.976
12 58.7 32.7/34.1 44.29 33.9 0.994
Claims (10)
1, a kind of compound recipe protease medicine for the treatment of hyperplasia of prostate, it is made by the weight portion of following raw material:
Hyaluronidase 0.3-1.5 bromelain 0.2-1.0 trypsin 0.2-2.5
Bacillus polymyxa Neutral proteinase 0.1-0.8 collagenase 0.2-1.5 gentamycin 0.02-0.1
Dexamethasone 0.02-0.1 deoxyribonuclease 0.1-0.5 chitosan 0.00-0.1
Terazosin 0.0-1.5 mannitol 0.0-2.0 agarose 0.2-1.2
TritonX 0.2-1.5.
2, a kind of compound recipe protease medicine for the treatment of hyperplasia of prostate according to claim 1 is characterized in that it is made by the weight portion of following raw material:
Hyaluronidase 1.5 bromelain 0.2 trypsin 0.5
Bacillus polymyxa Neutral proteinase 0.1 collagenase 0.2 gentamycin 0.02
Dexamethasone 0.1 deoxyribonuclease 0.1 chitosan 0.03
Terazosin 0.2 mannitol 0.5 agarose 0.4
TritonX 0.2.
3, a kind of compound recipe protease medicine for the treatment of hyperplasia of prostate according to claim 1 is characterized in that it is made by the weight portion of following raw material:
Hyaluronidase 0.5 bromelain 1.0 trypsin 1.5
Bacillus polymyxa Neutral proteinase 0.8 collagenase 0.5 gentamycin 0.02
Dexamethasone 0.02 deoxyribonuclease 0.5 chitosan 0.04
Terazosin 0.5 mannitol 1.8 agaroses 0.3
TritonX 0.2.
4, a kind of compound recipe protease medicine for the treatment of hyperplasia of prostate according to claim 1 is characterized in that it is made by the weight portion of following raw material:
Hyaluronidase 0.3 bromelain 0.3 trypsin 1.5
Bacillus polymyxa Neutral proteinase 0.5 collagenase 1.5 gentamycins 0.02
Dexamethasone 0.04 deoxyribonuclease 0.2 TritonX 0.5
Agarose 1.0.
5, a kind of compound recipe protease medicine for the treatment of hyperplasia of prostate according to claim 1 is characterized in that it is made by the weight portion of following raw material:
Hyaluronidase 1.5 bromelain 0.5 trypsin 0.2
Bacillus polymyxa Neutral proteinase 0.5 collagenase 0.5 gentamycin 0.02
Dexamethasone 0.05 deoxyribonuclease 0.4 chitosan 0.03
Terazosin 1.0 mannitol 1.8 agaroses 0.2
TritonX 0.5.
6, a kind of compound recipe protease medicine for the treatment of hyperplasia of prostate according to claim 1 is characterized in that it is made by the weight portion of following raw material:
Hyaluronidase 0.5 bromelain 0.8 trypsin 0.75
Bacillus polymyxa Neutral proteinase 0.5 collagenase 0.5 gentamycin 0.1
Dexamethasone 0.05 deoxyribonuclease 0.1 chitosan 0.08
Terazosin 1.5 mannitol 0.5 agarose 1.2
TritonX 0.5.
7, a kind of compound recipe protease medicine for the treatment of hyperplasia of prostate according to claim 1 is characterized in that it is made by the weight portion of following raw material:
Hyaluronidase 1.0 bromelain 0.6 trypsin 2.5
Bacillus polymyxa Neutral proteinase 0.5 collagenase 1.0 gentamycins 0.02
Dexamethasone 0.05 deoxyribonuclease 0.2 TritonX 1.0
Mannitol 1.6 agaroses 0.5.
8, a kind of compound recipe protease medicine for the treatment of hyperplasia of prostate according to claim 1 is characterized in that it is made by the weight portion of following raw material:
Hyaluronidase 1.2 bromelain 0.6 trypsin 0.75
Bacillus polymyxa Neutral proteinase 0.25 collagenase 1.5 gentamycins 0.05
Dexamethasone 0.05 deoxyribonuclease 0.5 chitosan 0.10
Terazosin 0.5 mannitol 1.0 agaroses 0.25
TritonX 1.5.
9, a kind of compound recipe protease medicine for the treatment of hyperplasia of prostate according to claim 1 is characterized in that it is made by the weight portion of following raw material:
Hyaluronidase 1.0 bromelain 1.0 trypsin 2.5
Bacillus polymyxa Neutral proteinase 0.5 collagenase 1.0 gentamycins 0.02
Dexamethasone 0.1 deoxyribonuclease 0.2 chitosan 0.06
Terazosin 0.5 mannitol 1.6 agaroses 0.5
TritonX 1.0.
10, a kind of preparation method for the treatment of the compound recipe protease medicine of hyperplasia of prostate, it comprises the following steps:
A, take by weighing above-mentioned each raw material in proportion;
B, mannitol and agarose are dissolved in respectively in the solvent, it is standby to sterilize;
C, preparation chitosan gel rubber slow releasing agent: the spirit of vinegar that at first is preparation 0.1mol/L; Next is to add 2% chitosan, stirring and dissolving; The 3rd is to regulate pH to 5.5-6.0 with the 1mol/L sodium hydroxide, is the spirit of vinegar chitosan solution; The 4th is the spirit of vinegar chitosan solution to be added in the terazosin stirring and dissolving;
D, in the buffer that contains calcium, zinc ion, add chitosan gel rubber slow releasing agent and hyaluronidase, bromelain, trypsin, Bacillus polymyxa Neutral proteinase, collagenase, gentamycin, dexamethasone, deoxyribonuclease, TritonX, dissolving and mixing respectively;
E, after degerming, detect the endotoxin content of preparation, freeze dried powder is made in qualified back under aseptic condition, packing is stand-by.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100608634A CN100341569C (en) | 2004-09-17 | 2004-09-17 | Compound protease medicine for treating prostate proliferation and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100608634A CN100341569C (en) | 2004-09-17 | 2004-09-17 | Compound protease medicine for treating prostate proliferation and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1616091A true CN1616091A (en) | 2005-05-18 |
| CN100341569C CN100341569C (en) | 2007-10-10 |
Family
ID=34764363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100608634A Expired - Lifetime CN100341569C (en) | 2004-09-17 | 2004-09-17 | Compound protease medicine for treating prostate proliferation and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100341569C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101238145B (en) * | 2005-06-14 | 2013-04-24 | 普罗陶克斯有限公司 | Use of modified pore-forming proteins in preparing medicine for treating or preventing benign prostatic hyperplasia |
| CN104840436A (en) * | 2015-06-11 | 2015-08-19 | 刘磊 | Medicine composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116615A (en) * | 1989-01-27 | 1992-05-26 | Immunolytics, Inc. | Method for treating benign prostatic hypertrophy |
| AUPR289601A0 (en) * | 2001-02-05 | 2001-03-01 | Commonwealth Scientific And Industrial Research Organisation | Method of tissue repair |
| CN1166407C (en) * | 2003-04-03 | 2004-09-15 | 武汉大学 | Application of agrose in preparing medicine for prostate hyperplosia |
-
2004
- 2004-09-17 CN CNB2004100608634A patent/CN100341569C/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101238145B (en) * | 2005-06-14 | 2013-04-24 | 普罗陶克斯有限公司 | Use of modified pore-forming proteins in preparing medicine for treating or preventing benign prostatic hyperplasia |
| CN104840436A (en) * | 2015-06-11 | 2015-08-19 | 刘磊 | Medicine composition |
| CN104840436B (en) * | 2015-06-11 | 2017-12-05 | 刘磊 | Pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100341569C (en) | 2007-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shim et al. | Literature review to optimize the autologous fat transplantation procedure and recent technologies to improve graft viability and overall outcome: a systematic and retrospective analytic approach | |
| CN1788688A (en) | Device and method for lowly invasively transplanting biological material | |
| CN1420933A (en) | Method of inducing angiogenesis by micro-organs | |
| CN1812800A (en) | Muscle derived cells(mdc) for promoting and enhancing nerve repair and regeneration | |
| CN107858329A (en) | The method of fractionation of fatty mescenchymal stem cell and the test solution used from fat | |
| CN109865033A (en) | A kind of external application medical ointment and its application in reparation diabetes wound | |
| US20140314724A1 (en) | Cell preparation for erectile dysfunction or sensory disorders of the lower urinary tract containing adipose tissue derived mesenchymal stem cells | |
| CN1897959A (en) | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions | |
| CN1616091A (en) | Compound protease medicine for treating prostate proliferation and its preparing method | |
| CN1283291C (en) | Compound preparation for bone fracture and its preparation method | |
| JP5560491B2 (en) | Keloid and hypertrophic scar radical cure | |
| CN1297324C (en) | Tissue engineering autologous complex skin and its preparation method | |
| CN111281884A (en) | Method for reducing insulin dosage of diabetic patient by using stem cell therapy | |
| CN106039293A (en) | Composition for repairing skin ulcers and preparation method thereof | |
| CN1562113A (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN108289934A (en) | Plasminogen dosage regimen for wound healing | |
| WO2002087661A1 (en) | A compound artificial liver system and the method for using the said system | |
| CN1646148A (en) | Drugs including anticancer agents and immunopotentiators and health foods and drinks | |
| CA2693382A1 (en) | Fused stem cells useful for the treatment of diabetes and methods thereof | |
| CN106562995A (en) | Preparation method for preparing swan embryos and application of swan embryos | |
| TWI526217B (en) | Cyanobacterial extract solution, pharmaceutical composition and use thereof | |
| WO2008121016A8 (en) | Oncological disease treating method | |
| CN1634299A (en) | Application of fenugreek total alkali extract in preparing medicine for ulcerative colitis and preparation method of colon targeted preparation | |
| CN111714520A (en) | Periplaneta americana preparation and preparation method and application thereof | |
| CN208404966U (en) | A kind of cell transplantation enhancing device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: WENZHOU SANTIAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WUHAN UNIVERSITY Effective date: 20070119 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070119 Address after: 325003 Liming Industrial Park, Lucheng District, Zhejiang, Wenzhou 55 Applicant after: Wenzhou Santian Pharmaceutical Co., Ltd. Address before: 430072 Hubei city of Wuhan province Wuchang Luojiashan Applicant before: Wuhan University |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YU WENLIN Free format text: FORMER OWNER: WENZHOU SANTIAN PHARMACEUTICAL CO., LTD. Effective date: 20120426 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 325003 WENZHOU, ZHEJIANG PROVINCE TO: 264200 WEIHAI, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120426 Address after: 501 room 6, 264200 Tonghua Road, torch hi tech Industrial Development Zone, Shandong, Weihai Province Patentee after: Yu Wenlin Address before: 325003 Liming Industrial Park, Lucheng District, Zhejiang, Wenzhou 55 Patentee before: Wenzhou Santian Pharmaceutical Co., Ltd. |